Monitoring with circulating tumor cells in the perioperative setting of patients with surgically treated stages I-IIIA NSCLC.

Yago Garitaonaindia,Ramón Aguado-Noya,Aranzazu Garcia-Grande, Mar Cordoba, Maria Jose Coronado Albi,Jose Luis Campo Cañaveral,Virginia Calvo,Mariola Blanco Clemente, Ruth Álvarez, Marta Peñas,Luis Chara,Ana Royuela,Mariano Provencio

Translational lung cancer research（2023）

引用 0|浏览14

暂无评分

摘要

Despite the large cohort of patients included in this study, CTC monitoring in the perioperative setting was not correlated with relapse, DFS or OS in our study, and therefore cannot be recommended as a reliable biomarker for minimal residual disease (MRD) after surgery.

查看译文

关键词

tumor cells,i–iiia nsclc,perioperative setting

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要